Transmitted HIV drug resistance- does the problem exists in Nepal?

  • Surendra Karki Infectious Disease Epidemiology Unit, Department of Epidemiology and Preventive Medicine, Monash University, Australia


1. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS. Nov 7 2003;17(16):2383-2388.

2. Xinhua. Hundreds of HIV patients stop antiretroviral treatment in Nepal. 2010;

3. Deshpande A, Karki S, Recordon-Pinson P, Fleury HJ. Drug Resistance Mutations in HIV Type 1 Isolates from Naive Patients Eligible for First Line Antiretroviral Therapy in JJ Hospital, Mumbai, India. AIDS Res Hum Retroviruses. May 16 2011.

4. Oelrichs RB, Shrestha IL, Anderson DA, Deacon NJ. The explosive human immunodeficiency virus type 1 epidemic among injecting drug users of Kathmandu, Nepal, is caused by a subtype C virus of restricted genetic diversity. Journal of Virology. Feb 2000;74(3):1149-1157.

5. Shahid A, Dixit SM, Gurbacharya VL, Karmacharya D, Ali S. HIV-1 Circulating Recombinant Form (CRF) in Nepal. Journal of Virology. Jun 15 2011;85:8458.

6. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;13 Suppl 2:25-36.
How to Cite
Karki, S. (2014). Transmitted HIV drug resistance- does the problem exists in Nepal?. Journal of Nepal Medical Association, 52(193), 755-756.
Letter to the Editor